Introduction
============

Craniopharyngioma of childhood are commonly cystic in nature. These tumors are histologically benign, corresponding to WHO grade I and are usually not life threatening. Benign lesions in the brain are considered cured when amenable to surgical resection, however even gross total resection of craniopharyngioma is not always curative and may be associated with significant additional morbidities (Müller, [@B43]). Craniopharyngioma diagnosed in childhood will affect the developing child, the maturing brain and body via effects on the visual, endocrinological, metabolic, and neurocognitive functions in a more significant way as compared to adults. Therefore the Hippocrates' basic principle "to help or at least to do no harm" is the ultimate challenge when determining the best means for treating childhood craniopharyngioma and minimizing morbidity is a major goal.

Hence the prospect of a minimally invasive intervention -- such as an endoscopic insertion of a catheter with a subcutanous Ommaya reservoir -- and subsequent instillation of substances inducing shrinkage of the craniopharyngioma cyst(s), seems a promising strategy. The following article reviews the experiences and outcomes of children treated with intracystic therapies providing a critical summary and an outline for potential future endeavors.

Methods
=======

A systematic review of the medical literature was performed to identify potentially relevant, all languages articles using Ovid MEDLINE and EMBASE from inception to July 2011 and Cochrane Central Register of Controlled Trials to third quarter 2011. The search strategy comprised a text search with medical subject headings (MeSH) and free text terms used in combination including craniopharyngioma, intracystic treatment, cyst\*, antineoplastic, and antibiotic. The total retrieval was 211 references from the 3 databases. All references were saved in an EndNote library used to identify the 69 duplicates for a total of 142 unique references. All references were examined for relevancy.

Results
=======

Neurosurgical aspects of intracystic catheter insertion
-------------------------------------------------------

Fenestration as a "minimal" surgical intervention in the treatment of cystic craniopharyngioma was employed by Cushing in 1930. He and others recognized early on that the benefit from this intervention was of short duration with recurrence of symptoms within a short period of time (Kramer et al., [@B35]). This still holds true in a recent study which confirmed high recurrence rates when surgery was limited to cyst fenestration even with combined adjuvant Gamma knife surgery (Park et al., [@B47]).

An insertion of a catheter into a cystic craniopharyngioma may prevail over the transient success of a cyst fenestration by allowing repetitive drainage of the tumor cyst and the opportunity of instillation of intracystic substances. Different neurosurgical techniques are employed for the placement of catheters.

Surgical strategies for intracystic catheter placement are reported in a retrospective review of 50 cystic craniopharyngioma patients treated at two French (Paris, Marseille) and three Brazilian (Belo Horizonte, Goiânia, São Paulo) institutions between 1990 and 2000. The authors distinguish three different patient groups according to the different surgical approaches. Although with limited certainty from the data provided, the study included mainly pediatric patients. There is an age range (9 months to 21 years) given for the 25 female patients; a median age of 10 years is indicated for the male patients. Group one (*n* = 26) had their catheters placed either via frontal or pterional craniotomy under direct vision. Group two (*n* = 14) underwent stereotactic placement and group three (*n* = 11) had free hand placement through a burr hole. All catheters were connected to either a Rickham (*n* = 23) or an Ommaya reservoir subcutaneously. One to two weeks after the surgical intervention a permeability study (injection of contrast medium into the cyst via reservoir) using either X-ray or CT was undertaken revealing contrast leakage or misplacement of the intracystic catheter in eight children (16.3%). This study did not find a difference in complications between the three different surgical methods and reported that no other catheter placement related complication occurred in this series (Zanon et al., [@B61]).

Pettorini et al. ([@B49]) advocate that neuroendoscopic positioning of the catheter is a safer option than open or stereotactic approaches. In their case series of eight patients (five children with a mean age 3.8 years) with symptomatic cystic craniopharyngioma the placement of the catheter via endoscopy with a Storz rigid ventriculoscope was without complications except one technical failure (12.5%). The technical failure occurred in a child with an extensively calcified cyst wall that made positioning of the catheter impossible. For planning reasons a pre-op CT seems important as calcifications could be missed on MRI scans which are commonly the preferred imaging modality in children in order to minimize radiation exposure. Other advantages in using the endoscopic approach are the possibility to perform a septostomy at the same time, an intervention that establishes connection between lateral ventricles and subsequently facilitates successful shunting.

Stereotactic endoscopic technique as a safe and effective procedure for catheter insertion in cystic craniopharyngioma is supported by Joki et al. ([@B32]). Hellwig et al. ([@B22]) describe effective management in more than 70 cystic intracerebral space occupying lesions without major tissue traumatization. They reported an operative morbidity of less than 3% and no operative mortality.

There are anatomic constraints that may limit the stereotactic accessibility of a craniopharyngioma cyst which relate to infra- or suprasellar location and the vulnerability of the adjacent critical structures such as optic apparatus, pituitary gland, and hypothalamus (Floyd et al., [@B14]).

The experience of the operating neurosurgeon in a certain technique will ultimately affect the outcome. Interestingly in a study by Sanford ([@B52]) the experience of the operating neurosurgeon was proven statistically significant with respect to the quality of life of craniopharyngioma patients.

Instillation of substances
--------------------------

The majority of cystic craniopharyngioma arise from squamous epithelium (Ingraham and Scott, [@B29]; Kramer et al., [@B35]; Louis et al., [@B39]). Intracystic instilled substances should have the ability to destroy the secretive properties of the epithelial cell lining to induce cyst shrinkage and ideally subsequent adhesion of the cyst wall. Substances should remain within the cyst and should not cause any harm to the surrounding brain in case of leakage. Substances used for cystic craniopharyngiomas have been radioisotopes, Bleomycin, and Interferon (IFN) (Table [1](#T1){ref-type="table"}).

###### 

**Intracystic treatment modalities in craniopharyngiomas -- retrospective reviews including children**.

  Reference                                                   Patients (kids)   *Median*/mean age (range) in years   CR     PR     *Median*/mean f/up (range) in years   *Median*/mean PFS (range) in years                   Reported complications or toxicities
  ----------------------------------------------------------- ----------------- ------------------------------------ ------ ------ ------------------------------------- ---------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  **ISOTOPES**                                                                                                                                                                                                                
  Pollock et al. ([@B50])                                     30 (10)           35 (3--70)                           0.10   0.83   3.1 (0.6--9.7)                        NR                                                   Three new behavioral problems, visual decline, three new onset DI
  Voges et al. ([@B59])                                       62 (32)           *17* (4--71)                         0.45   0.35   *11.9* (1.5--16.4)                    NR                                                   Three amaurosis, one visual field cut, three endocrine deficits, one death 9 months after treatment
  Hasegawa et al. ([@B20])                                    49 (15)           29 (3--74)                           0.17   0.59   4.1                                   NR                                                   Visual or endocrine deterioration
  Julow et al. ([@B33])                                       60 (13)           27.7 (2.9--67.5)                     0.45   0.30   NR                                    NR                                                   Three visual deterioration, six transient CN III palsy, one death/meningoventriculitis 6 weeks after intervention, two hypothalamic/thalamic vascular injury
  Derrey et al. ([@B13])                                      42 (11)           38.7 (5--85)                         0.44   0.44   3.6 (0.7--12.3)                       NR                                                   Two septic meningitis, two chemical meningitis, one intracranial hypertension, two central hyperthermia; three visual acuity or field decline, one memory loss
  Barriger et al. ([@B5])                                     19 (NR)           20 (3--54)                           0.05   0.26   *5.2* (0.7--11.3)                     *0.8* (0.1--4.5)                                     Six increased pituitary deficiencies, one new field deficit
  **BLEOMYCIN**                                                                                                                                                                                                               
  Takahashi et al. ([@B57])[\*](#tfn1){ref-type="table-fn"}   \(7\)             8.4 (2--13)                          NR     NR     NR (21--26)                           12 (0.1--26)[^\#^](#tfn2){ref-type="table-fn"}       Transient mild fever
  Hader et al. ([@B17])                                       \(9\)             8.4 (2.5--14)                        0.14   0.71   3 (0.5--5)                            NR                                                   Two transient headaches and fever, one panhypopituitarism
  Mottolese et al. ([@B41])                                   24 (20)           14.3 (0.25--64)                      0.38   0.63   5                                     5 (2--10)                                            One blindness (after toxic dose) [+](#tfn3){ref-type="table-fn"} 
  Park et al. ([@B46])                                        10 (5)            30.2 (3--65)                         NR     NR     2.8 (1--6.6)                          NR                                                   One visual disturbance, one cerebellar infarction/death, one hypersomnia/memory impairment, one transient mental changes, one bedridden
  Mottolese et al. ([@B42])                                   \(24\)            NR (6--16)                           0.50   0.25   6.7 (1--14)                           NR                                                   One blindness (after toxic dose)[+](#tfn3){ref-type="table-fn"}; three new onset of DI, 11 endocrine insufficiency, visual deterioration
  Takahashi et al. ([@B58])                                   \(11\)            NR (2--14)                           0.27   0.64   NR (3--16)                            NR                                                   One hypothalamic--pituitary insufficiency/death during f/up
  Hukin et al. ([@B25])                                       \(17\)            *6* (1--14)                          0.29   0.35   *5* (0.5--10.2)                       *0.7* (0.3--6.1)[^\$^](#tfn4){ref-type="table-fn"}   Decreased level of consciousness/panhypopituitarism, one multiple CN deficits/hemiparesis
  Hsu et al. ([@B24])                                         \(9\)             *7.8* (3.3--11.8)                    NR     NR     *3.7* (0.8--6.6)                      *2.4* (0.2--6.6)                                     NR
  **INTERFERON**                                                                                                                                                                                                              
  Cavalheiro et al. ([@B10])                                  \(9\)             10 (1.8--18)                         0.78   0.22   1.8 (1--3.5)                          NR                                                   One arthralgia/chronic fatigue/depression
  Ierardi et al. ([@B28])                                     \(21\)            10 (1--19)                           0.50   0.50   2.25 (0.5--4)                         NR                                                   NR
  Cavalheiro et al. ([@B11])                                  \(60\)            11 (1.6--18)                         NR     0.78   3.7 (0.3--7)                          NR                                                   Transient headache/fever/fatigue/arthritis; eight new endocrinological dysfunction

*\*Including f/up data provided in Takahashi et al. ([@B58])*.

*^\#^Estimate from authors based on provided data*.

*^+^Likely same patient*.

*^\$^Refers to 12 patients treated at the time of the initial diagnosis*.

*NR, not reported; PFS, progression free survival; CR, complete response; PR, partial response (≥50% shrinkage); f/up, follow-up; CN, cranial nerve*.

Intracystic instillation of β *emitting radioisotopes* including aurum^198^, rhenium^186^, yttrium^90^, and phosphorus^32^ has been reported successful in inducing craniopharyngioma cyst shrinkage in multiple studies over more than four decades (Backlund, [@B3], [@B4]; Musolino et al., [@B45]; Voges et al., [@B59]; Hasegawa et al., [@B20]).

While phosphorus^32^ is the only β emitting radionucleotide available for use in the USA, rhenium^186^, yttrium^90^, and phosphorus^32^ are available and used in Europe (France/Hungary/Germany) (Voges et al., [@B59]; Julow et al., [@B33]; Derrey et al., [@B13]). Physical characteristics of β emitting radioisotopes may determine preferences. Some authors favor phosphorus^32^ with a lower energy (mean β energy of 0.69 MeV), longer half life (14.3 days), and less tissue penetration (2--8 mm; Pollock et al., [@B50]) while others argue that yttrium^90^ (mean β energy of 0.93 MeV, 2.7 days half life, tissue penetration 11 mm) is superior due to its higher emitting dose during a shorter time period (Blackburn et al., [@B8]). Clinical studies, mostly institutional retrospective series, are equivocal regarding the clinical superiority of a radioisotope. Voges et al. ([@B59]) observed no cyst response to intracystic rhenium^186^, while intracavitary irradiation using yttrium^90^ or phosphorous^32^ was highly effective resulting in 79.5% response rates. In a more recent study including 11 children within 42 eligible patients, the instillation of colloidal rhenium^186^ resulted in 74% response rate including 17 patients with complete cyst retraction and 12 patients with \>50% reduction in cyst volume (Derrey et al., [@B13]). Barriger et al. ([@B5]) report an overall cyst control rate of 67% with intracystic phosphorus^32^ in 19 patients between 3 and 54 years of age.

Radioisotope doses require adjustment to cyst volume. The optimal prescribed dose to the cyst wall is 200--300 Gy (Hechtman et al., [@B21]; Sadeghi et al., [@B51]) up to 400 Gy with significant increased risks especially to the optic apparatus once doses surpass 400 Gy (Derrey et al., [@B13]; Floyd et al., [@B14]). There is evidence that cyst volumes exceeding 100 ml will not respond well (Albright et al., [@B1]).

Instillation of phosphorus^32^ into a recurrent infrachiasmatic cystic craniopharyngioma of a 36-old-female via an neuroendoscopic transnasal route was described recently (Floyd et al., [@B14]) and is certainly an elegant minimal invasive intervention. A therapeutic effect was achieved with one instillation only and therefore the insertion of a permanent catheter with reservoir was not required. However a catheter implantation is usually employed for radioisotopes injection and removal (Derrey et al., [@B13]).

Access to radioisotopes is only available in a limited number of institutions requiring sophisticated equipment and a multidisciplinary team of experts and there is advocacy using this treatment approach only for tumors that recur after both surgery and external beam radiation therapy (Becker et al., [@B6]; Merchant et al., [@B40]).

In 1974 the effect of *bleomycin* for cultured craniopharyngioma cells and intracystic concentration of bleomycin was published by Kubo et al. ([@B36]). Based on their morphological observations of destruction of cell arrangement, cytolysis, and karyopyknosis they concluded its local cytotoxic potency to craniopharyngiomas. They were the first to report on intracystic bleomycin treatment in an 8-year-old boy with craniopharyngioma who had failed radiation. A mixture of bleomycin, dextran sulfate, and dexamethasone was injected into his cyst via ommaya reservoir. Treatment was given twice during the first week. No significant side effects were observed and subsequently intracystic injections were given 5 days during the second week, followed by instillations every second day on an outpatient basis. A total dose of 30 mg bleomycin was administered resulting in partial cyst reduction as evaluated with pneumocystography. The boy was reported well at 1 month follow-up.

Takahashi et al. ([@B57]) published a case series on seven children with craniopharyngioma treated with intracystic instillation of Bleomycin.By labeling Bleomycin with cobalt-57 and subsequent measurements with a gamma-ray camera a 3 h half life of intracystic Bleomycin with a drop to 10% of the initial activity 24 h later was calculated. This surveillance determined the subsequent treatment regimen administering intracystic instillation of 1--5 mg bleomycin every other day. The authors further observed that with ongoing intracystic instillation of bleomycin the initial motor-oil like fluid content changed to nearly colorless fluid and initial high lactate dehydrogenase (LDH) levels dropped. Hence treatment was given until cystic fluid became almost colorless and LDH levels decreased below 1000 units. The seven children received a mean dose of 46 mg of intracystic bleomycin ranging from 13 to 95 mg. Four children had sustained response without evidence of progression at 2, 4, and 7 years follow-up. Three children died, two of them due to recurrent disease 1.5 and 2 years later respectively. One child died 1.5 months later without evidence of progression; further details are lacking. Autopsies in two of the children did not reveal any bleomycin associated changes in the adjacent brain structures.

Since Takahashi's publication in 1985 several pediatric case reports (Cavalheiro et al., [@B12]; Savas et al., [@B53]; Alen et al., [@B2]) and retrospective institutional case series confirmed intracystic bleomycin's effectiveness in inducing craniopharyngioma cyst shrinkage with sustained response rates in children (Takahashi et al., [@B57], [@B58]; Hader et al., [@B17]; Franzini et al., [@B15]; Mottolese et al., [@B41], [@B42]; Hernandez et al., [@B23]; Park et al., [@B46]; Hukin et al., [@B26], [@B25]; Kim et al., [@B34]; Hsu et al., [@B24]; Yang et al., [@B60]). All studies refer to small sample sizes including a maximum of 22 pediatric patients (Franzini et al., [@B15]) with five studies reporting response to treatment in all patients (Mottolese et al., [@B41]; Park et al., [@B46]; Hukin et al., [@B26]; Takahashi et al., [@B58]; Kim et al., [@B34]). Complete response rates in children vary from 29% as provided by the Canadian experience (Hukin et al., [@B25]) to 67% (Mottolese et al., [@B42]) in the Lyon experience, where 12 of 18 children showed disappearance of the cyst with maintained responses at a mean follow-up of 6 years 8 months.

The schedules of bleomycin administration and doses vary and range from daily to weekly administrations with single doses ranging from 1 to 15 mg and total doses ranging from 14.5 to 180 mg per course (Takahashi et al., [@B57]; Jiang et al., [@B31]; Park et al., [@B46]). No standardized regimen has been established. Of note is that the former bleomycin mg dose was labeled a misnomer and should be substituted by Unit (1 mg equals 1 U). Stefanou underscored the considerable problems and dangers due to different bleomycin nomenclature in the US, Europe, and Australia and advocated for standardization as a mean to minimize dosing errors (Stefanou and Siderov, [@B55]).

Several studies investigated intracystic fluid LDH to prognosticate tumor response. While some studies observed decreased LDH levels consistent with response and increased LDH levels with recurrence (Takahashi et al., [@B57]; Park et al., [@B46]) others did not confirm LDH levels reflective of tumor response (Cavalheiro et al., [@B12]; Mottolese et al., [@B41]; Jiang et al., [@B31]; Caceres, [@B9]).

Intracystic bleomycin is usually well tolerated and most common acute side effects include mild headaches (with or without nausea/vomiting) and transient fever. However serious concerns relate to the risk of leakage of the neurotoxic bleomycin into the cyst surrounding parenchyma with associated morbidities and even mortality. Despite verification of appropriate positioning of the catheter intracystic bleomycin is associated with a risk of significant toxicities including transient and persistent hypothalamic injury (Haisa et al., [@B18]; Park et al., [@B46]; Lafay-Cousin et al., [@B37]), seizures and hemiparesis (Jiang et al., [@B31]; Park et al., [@B46]; Belen et al., [@B7]; Hukin et al., [@B25]), panhypopituitarimus (Hader et al., [@B17]; Hukin et al., [@B25]), blindness (Mottolese et al., [@B41]; Belen et al., [@B7]), and death (Savas et al., [@B54]). A prospective randomized study evaluating intracystic bleomycin (*n* = 5), intracystic radiotherapy with phosphorus^32^ (*n* = 5), and a combination of both substances (*n* = 9) revealed severe complications for the combined therapy resulting in thalamic infarction and death in two patients (Jiang et al., [@B31]).

Jakacki et al. ([@B30]) used *subcutanous IFN* for the treatment of cystic craniopharyngioma based on the fact that craniopharyngioma and squamous cell skin carcinoma originate from the same cells and evidence of clinical activity of IFN in squamous cell skin carcinoma in early trials. In their study 15 craniopharyngioma patients (4.2--19.8 years old) underwent daily subcutanous IFN-α 2a (8,000,000 U/m^2^) injections. Three patients could not be evaluated for response. Of the remaining 12 patients, 3 patients had a radiologically confirmed response to IFN. All patients experienced fever during the first few days of treatment, usually accompanied by chills and myalgias. Seven patients required temporary discontinuation of the drug and/or dose reductions.

*Intracystic instillation of interferon* was first used by Cavalheiro and colleagues who published the first and largest experiences on children with cystic craniopharyngiomas (Cavalheiro et al., [@B10], [@B11]; Ierardi et al., [@B28]). Their most recent publication (Cavalheiro et al., [@B11]) included 60 children with a mean age of 11 years (20 months--18 years) who were treated at three different institutions (Sao Paulo/Brazil, Santiago/Chile, Rome/Italy) from 2000 to 2009. Twenty-nine of the 60 patients received intracystic IFN after initial surgery (*n* = 18) or bleomycin treatment (*n* = 3) had failed and 31 were treated with IFN as a first line treatment. In 37 patients cyst volume was measured before and after therapy. The mean cyst volume of 27.7 ml (3.3--134.5) before treatment decreased to a mean volume of 9.6 ml (0.14--70.7) after therapy. While in 47 children (78%) more than 50% cyst shrinkage was achieved at completion of therapy, 13 children progressed and required surgical intervention. Only one-third of the patients experienced some side effects consisting of either headaches (*n* = 6), palpebral edema (5), fever (5), chronic fatigue (1), or arthritis (1) not necessitating discontinuation of treatment. One patient required optic decompression due to lack of visual improvement despite cyst shrinkage and eight patients developed new endocrinological dysfunctions. There was no mortality.

Based on Cavalheiros experience and initial publication a standard of care protocol was developed for intracystic IFN administration (Figure [1](#F1){ref-type="fig"}) in Toronto. The former intracystic treatment with bleomycin injection was discontinued due to our experience of bleomycin associated neurotoxicity (Lafay-Cousin et al., [@B37]). Roferon-A® (IFN-α 2a), the product used by Cavalheiro et al. ([@B10], [@B11]) is not available in Canada. Intron-A® (IFN-α 2b) is available in Canada and although not specifically studied in the treatment of craniopharyngiomas, the ready to use formulation has been given intraventriculary via Ommaya reservoir for subacute sclerosing panencephalitis (SSPE; Gascon, [@B16]). In this randomized clinical trial including 121 SSPE patients with a median age 8.5 (3--22) years, IFN-α 2b was initiated with a 5-day escalating regime from 100,000 U/m^2^ on day 1 to 1,000,000 U/m^2^ on day 5 followed by treatment of 1,000,000 U/m^2^ twice a week for 6 months. Fifty-nine patients were randomized to the IFN group. The main adverse effect reported was hyperpyrexia (*n* = 7) an expected side effect and well managed with regular antipyretics. From a clinical perspective, IFN-α 2a and IFN-α 2b are considered interchangeable for their licensed indications, at equivalent doses. An "ideal" formulation of IFN has not been developed for administration via an Ommaya reservoir.

![**SickKids standard of care protocol for intracystic interferon administration**.](fendo-03-00039-g001){#F1}

Since adoption of intracystic IFN at our institution six children between 4 and 18 years of age (mean 10.8 years) were treated. Response was measurable in five children with one complete response (\>90% cyst shrinkage; Figure [2](#F2){ref-type="fig"}), three partial response (\>50% shrinkage), and one stable disease. Sustained response was achieved after two to four treatment cycles with a median follow-up of 17 (1--30) months. All patients suffered manageable episodes of headaches, one associated with nausea and vomiting in the initial treatment period. None of the children suffered new endocrinological dysfunction, evidence of hypothalamic damage and none of them is obese.

![**Child with complete maintained response after 2 courses with intracystic interferon**.](fendo-03-00039-g002){#F2}

Interferon belongs to a family of proteins with antiproliferative and immunomodulatory functions and its efficacy has been explained via FasL mediated activation of the apoptotic pathway (Ierardi et al., [@B28]). As such Pettorini et al. ([@B48]) investigated protein content of the cystic fluid in six pediatric craniopharyngioma patients (mean age 4.5 years) and reported change in fluid content. Those three children who were treated with intracystic IFN resulting in near complete response after a one 4-week lasting course had significant decrease in their total alpha-defensins (1--3) determined as relevant components of cyst fluids while the untreated control (*n* = 3) showed increased nanomoles of alpha-defensins.

Conclusion
==========

Intracystic treatment options for cystic craniopharyngioma provide data suggestive of durable cyst shrinkage and benefit beyond a pure volume reduction due to repeated fluid aspirations. The effect however is limited to the cystic craniopharyngioma portion without an effect on the solid component. There are multiple challenges relating to technical practicalities: Multicystic occurrence may limit treatment to one cyst only and therefore this approach does not provide the clinical benefit as wished. The thickness of the cyst wall may not allow successful penetration of the scope/catheter into the cyst and different catheter designs make the correct intracystic positioning of the catheter and its holes difficult. Intraoperative ultrasound and computer tomography (CT) have aided to confirm correct catheter position; however volume changes during subsequent treatment may influence the intracystic catheter tip location.

Most institutions will perform a permeability study prior to the start of intracystic treatment. The timing of the permeability study/dye test depends on the specific institution and ranges from 5 days postoperatively to several weeks later (Caceres, [@B9]; Cavalheiro et al., [@B11]). A permeability study refers to a CT done after contrast is injected into the craniopharyngioma cyst to confirm that contrast will remain within the cyst and not leak outside (Figure [3](#F3){ref-type="fig"}). Leakage documented on an early performed permeability study has often resolved without further intervention on a follow-up test after some weeks (Hader et al., [@B17]). Outflow of substances may occur during treatment either as a result of cyst shrinkage exposing catheter holes outside of the cyst or as a result of increased permeability of the cyst wall (Lafay-Cousin et al., [@B37]).

![**Permeability study**.](fendo-03-00039-g003){#F3}

Hence, despite all diligence, leakage of an intracystic substance remains a potential risk. Therefore a non-neurotoxic intracystic medication such as IFN presents a safer treatment option than radioisotopes or bleomycin and achieved impressive 78% complete and partial response rates after a one to nine treatment cycles (average 5; Cavalheiro et al., [@B11]).

Is cyst shrinkage the appropriate response measurement? A reduced cyst size will reduce increased pressure to the neighborhood structures and should translate into clinical benefit regarding visual, neurocognitive, endocrine, and metabolic function. However Cavalheiro et al. ([@B11]) describe visual or endocrinological worsening in one and eight children respectively despite response to intracystic treatment.

Literature reviews concerning intracystic craniopharyngioma treatment strategies published over the recent years (Caceres, [@B9]; Hargrave, [@B19]; Linnert and Gehl, [@B38]; Steinbok and Hukin, [@B56]) capture the challenge of combining retrospective data from different institutions that refer to different doses, schedules, response definitions, and meaning of success. Cystic response and final outcome may not necessarily correlate. Prognostic marker need yet to be identified (Ierardi et al., [@B28], [@B27]; Pettorini et al., [@B48]). Furthermore the role and value of intracystic treatment in postponing more aggressive surgery or radiation therapy will need to be defined.

Comparisons and reliable conclusions will remain difficult unless we as a medical community are agreeable on systematic evaluations and definitions. While randomized clinical trials are the gold standard for evaluation of best treatment strategies, they are certainly difficult in the context of rare tumors. Even so thoughts should be given to potential national and international cooperation for standardized intracystic treatment strategies. It's been 7 years that a European consensus was achieved regarding prospective data collection and definition of parameter for craniopharyngioma at a meeting of the International Society for Pediatric Oncology (SIOP; Müller et al., [@B44]). It is time to expand consensus on prospective data collection on craniopharyngioma patients to an international level. In doing so we will increase the size of comparable study cohorts, be able to evaluate meaningful differences and contribute to improved tailored patient care and wellbeing.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Sincere thanks to Dr. Takaaaki Yanagisawa for providing translation of the original Japanese publications on bleomycin, to Ms. Anne H. Longo for her excellent pharmacological assistance and to Mrs. Elizabeth M. Uleryk for her extensive literature research.

[^1]: Edited by: Ursula B. Kaiser, Brigham and Women's Hospital, USA

[^2]: Reviewed by: Edward Raymond Laws, Brigham and Women's Hospital, USA; Laurence Katznelson, Stanford University, USA

[^3]: This article was submitted to Frontiers in Pituitary Endocrinology, a specialty of Frontiers in Endocrinology.
